Business, energy, technology, markets and global industry news from Business News Today

antibody-drug conjugates

PharmaDeviceNews antibody-drug conjugates
Representative image of oncology researchers reviewing molecular therapy data, reflecting Pfizer and Innovent Biologics’ global collaboration to advance antibody-drug conjugates, multispecific antibodies, and next-generation cancer medicines.
Pharma & Biotech

Why Pfizer’s $10.5bn Innovent Biologics deal matters for the next wave of cancer medicines

Pfizer’s $10.5bn Innovent alliance deepens its oncology reset. Can early ADC and multispecific bets become global cancer drugs?

Read More
Representative image of oncology biomarker testing and antibody-drug conjugate research. Antengene’s ATG-022 Phase III clearance highlights rising competition in CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer.
Pharma & Biotech

Why CLINCH-3 matters for Antengene’s oncology strategy and gastric cancer ambitions

Antengene’s ATG-022 enters pivotal testing in gastric cancer, testing whether CLDN18.2 ADCs can stand out in a crowded oncology field.

Read More
Representative image of oncology research and blood cancer diagnostics. AbbVie’s DECNUPAZ approval highlights how CD123-targeted antibody-drug conjugates could reshape treatment options for blastic plasmacytoid dendritic cell neoplasm.
Pharma & Biotech

How AbbVie’s DECNUPAZ approval changes the treatment conversation in aggressive BPDCN

Find out how AbbVie’s DECNUPAZ approval could change BPDCN treatment while raising new safety and adoption questions.

Read More
Pharma & Biotech

Can RenSuper help Biocytogen reduce the bottlenecks in antibody development?

Biocytogen is turning antibody discovery into an AI-led industrial workflow. RenSuper could speed biologics R&D, but validation risk remains.

Read More
Representative image: Scientists review antibody-drug conjugate research in an oncology laboratory as Gilead Sciences’ Tubulis acquisition sharpens focus on next-generation ADC platforms, solid tumour pipelines and cancer drug development strategy.
Pharma & Biotech

Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy

Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.

Read More
Representative image: An oncology specialist reviews treatment information with a breast cancer patient in a clinical setting, reflecting Gilead Sciences’ Trodelvy regulatory progress in first-line metastatic triple-negative breast cancer care.
Pharma & Biotech

Gilead’s Trodelvy gains EU regulatory momentum, but the first-line TNBC fight is only beginning

Gilead’s Trodelvy may move earlier in metastatic TNBC. The EU signal could reshape first-line ADC use, but adoption questions remain.

Read More
Representative image: A clinician reviews bladder cancer imaging in a modern oncology setting, reflecting Merck’s KEYTRUDA plus Padcev EU regulatory milestone for cisplatin-ineligible muscle-invasive bladder cancer patients.
Pharma & Biotech

Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer

Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.

Read More
Pharma & Biotech

Regeneron’s $2.2bn Parabilis pact signals rising interest in next-generation conjugates

ADCs changed cancer delivery. Regeneron and Parabilis now want Helicon peptides to push conjugates inside harder-to-drug biology.

Read More
Pharma & Biotech

Can payload-linker manufacturing help Piramal Pharma Solutions reset CDMO momentum?

ADC demand is rising, but manufacturing remains a bottleneck. Piramal Pharma Solutions is betting Riverview can narrow that gap.

Read More
Representative image of AI-powered digital pathology and oncology biomarker analysis, illustrating how Daiichi Sankyo and Waiv’s ADC collaboration could support smarter patient selection in precision cancer drug development.
Pharma & Biotech

Why Daiichi Sankyo’s Waiv collaboration matters for the next phase of ADC oncology trials

ADC trials need sharper patient selection. Daiichi Sankyo’s Waiv deal tests whether AI pathology can find response signals earlier.

Read More